Benznidazol (Ro 07-1051) (Synonyms: NSC 299972, Ro 07-1051)

Benznidazol (Ro 07-1051) is an antiparasitic medication, with an IC50 of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease[1][2].

Benznidazole (100 mg/kg/day, p.o., 30 days) produces a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart, in mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12 isolate and treated at 180 days post infection (p.i.) (i.e. chronic phase) with Benznidazole[1].|| Animal Model:|Mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12[1]|Dosage:|100 mg/kg/day |Administration:|Orally for 30 days|Result:|Produced a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart.

[1]. Bustamante JM, et al. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int J Antimicrob Agents. 2007 Jun;29(6):733-7. [2]. Luna KP, et al. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica. 2009 Sep;29(3):448-55.